JP2019531704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531704A5 JP2019531704A5 JP2019504812A JP2019504812A JP2019531704A5 JP 2019531704 A5 JP2019531704 A5 JP 2019531704A5 JP 2019504812 A JP2019504812 A JP 2019504812A JP 2019504812 A JP2019504812 A JP 2019504812A JP 2019531704 A5 JP2019531704 A5 JP 2019531704A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- immunomodulatory polypeptide
- binding peptide
- binding
- subunit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 74
- 102000004196 processed proteins & peptides Human genes 0.000 claims 35
- 229920001184 polypeptide Polymers 0.000 claims 31
- 230000002519 immonomodulatory effect Effects 0.000 claims 28
- 210000004027 cell Anatomy 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 230000008685 targeting Effects 0.000 claims 10
- 108091023040 Transcription factor Proteins 0.000 claims 9
- 102000040945 Transcription factor Human genes 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- 239000003623 enhancer Substances 0.000 claims 7
- 150000007523 nucleic acids Chemical group 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 102000005962 receptors Human genes 0.000 claims 6
- 108020003175 receptors Proteins 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 4
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- OVXIMRGEBNSORH-UHFFFAOYSA-N 2-[[2-[2-[[2-[[1-[1-[5-amino-2-[[2-amino-3-(1h-indol-3-yl)propanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylp Chemical compound CCC(C)C(C(O)=O)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C1N(C(=O)C(CCC(N)=O)NC(=O)C(N)CC=2C3=CC=CC=C3NC=2)CCC1 OVXIMRGEBNSORH-UHFFFAOYSA-N 0.000 claims 3
- 102000019034 Chemokines Human genes 0.000 claims 3
- 108010012236 Chemokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 229960004641 rituximab Drugs 0.000 claims 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 2
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 108010065524 CD52 Antigen Proteins 0.000 claims 2
- 102000013135 CD52 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 102000012804 EPCAM Human genes 0.000 claims 2
- 101150084967 EPCAM gene Proteins 0.000 claims 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims 2
- 108010025832 RANK Ligand Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 102100029198 SLAM family member 7 Human genes 0.000 claims 2
- 101150057140 TACSTD1 gene Proteins 0.000 claims 2
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960002450 ofatumumab Drugs 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 102100022749 Aminopeptidase N Human genes 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 101000841393 Candida albicans Probable NADPH dehydrogenase Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 101000866618 Homo sapiens 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Proteins 0.000 claims 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 1
- 101000765010 Homo sapiens Beta-galactosidase Proteins 0.000 claims 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 1
- 101000616556 Homo sapiens SH3 domain-containing protein 19 Proteins 0.000 claims 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 1
- 102100021782 SH3 domain-containing protein 19 Human genes 0.000 claims 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 claims 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 claims 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 229940126530 T cell activator Drugs 0.000 claims 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 108010039524 chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960004137 elotuzumab Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960000513 necitumumab Drugs 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 230000008650 pH stress Effects 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229950010968 romosozumab Drugs 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023024001A JP2023062104A (ja) | 2016-07-29 | 2023-02-20 | 免疫調節ポリペプチドならびに関連する組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369017P | 2016-07-29 | 2016-07-29 | |
| US62/369,017 | 2016-07-29 | ||
| PCT/US2017/044549 WO2018023093A1 (en) | 2016-07-29 | 2017-07-28 | Immunomodulatory polypeptides and related compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023024001A Division JP2023062104A (ja) | 2016-07-29 | 2023-02-20 | 免疫調節ポリペプチドならびに関連する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531704A JP2019531704A (ja) | 2019-11-07 |
| JP2019531704A5 true JP2019531704A5 (cg-RX-API-DMAC7.html) | 2020-09-03 |
| JP7295795B2 JP7295795B2 (ja) | 2023-06-21 |
Family
ID=59631857
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504812A Active JP7295795B2 (ja) | 2016-07-29 | 2017-07-28 | 免疫調節ポリペプチドならびに関連する組成物および方法 |
| JP2023024001A Pending JP2023062104A (ja) | 2016-07-29 | 2023-02-20 | 免疫調節ポリペプチドならびに関連する組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023024001A Pending JP2023062104A (ja) | 2016-07-29 | 2023-02-20 | 免疫調節ポリペプチドならびに関連する組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12304935B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3490585B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7295795B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110087672A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017301880C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3031955A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2951552T3 (cg-RX-API-DMAC7.html) |
| MA (1) | MA45779A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019001185A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018023093A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| WO2018023093A1 (en) | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| WO2019010224A1 (en) | 2017-07-03 | 2019-01-10 | Torque Therapeutics, Inc. | FUSION MOLECULES TARGETING IMMUNE REGULATORY CELLS AND USES THEREOF |
| CN112236151A (zh) | 2018-03-14 | 2021-01-15 | 西雅图儿童医院（Dba西雅图儿童研究所） | 用于肿瘤特异性T细胞免疫疗法的IL-13受体α2(IL13RA2)嵌合抗原受体 |
| KR20200131851A (ko) * | 2018-03-14 | 2020-11-24 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | Il-13 수용체 알파 2 표적화된 제타카인 지정 t 세포 면역요법 |
| WO2019222296A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| WO2019236577A2 (en) | 2018-06-04 | 2019-12-12 | Intrexon Corporation | Muc16 specific chimeric antigen receptors and uses thereof |
| CN109306016B (zh) * | 2018-08-15 | 2021-10-22 | 华东师范大学 | 共表达细胞因子il-7的nkg2d-car-t细胞及其用途 |
| AU2019336229A1 (en) * | 2018-09-07 | 2021-03-18 | Sotio, LLC | Chimeric receptor polypeptides in combination with trans metabolism molecules modulating intracellular lactate concentrations and therapeutic uses thereof |
| WO2020181983A1 (zh) * | 2019-03-12 | 2020-09-17 | 重庆精准生物技术有限公司 | 缺氧调控启动子及其应用 |
| CN111848811B (zh) * | 2019-04-27 | 2024-10-01 | 张晋宇 | 一种蛋白质异二聚体及其用途 |
| AU2020279112A1 (en) | 2019-05-17 | 2021-12-02 | Xencor, Inc. | IL-7-Fc-fusion proteins |
| CN112294760B (zh) * | 2019-07-26 | 2025-12-12 | 宁波新致生物科技有限公司 | 一种液体制剂及其应用 |
| US20230312685A1 (en) * | 2019-10-25 | 2023-10-05 | Mayo Foundation For Medical Education And Research | Bi-Peptide with Affinity to Extracellular Matrix Proteins or Cells and to Growth Factors for Tissue Healing and Regeneration |
| KR20220109436A (ko) | 2019-12-03 | 2022-08-04 | 에보텍 인터내셔널 게엠베하 | 인터페론-결합된 항원 결합 단백질 및 이의 용도 |
| WO2021115333A1 (zh) * | 2019-12-10 | 2021-06-17 | 苏州克睿基因生物科技有限公司 | 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用 |
| WO2021127495A1 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| CN111153961B (zh) * | 2020-01-08 | 2022-02-18 | 郑州大学 | 一种亲和pd-1的肽及其应用 |
| WO2021154455A1 (en) * | 2020-01-30 | 2021-08-05 | Purdue Research Foundation | Ligand-mediated delivery of therapeutic proteins and the uses thereof |
| CN111533785B (zh) * | 2020-02-11 | 2022-03-08 | 北京市肿瘤防治研究所 | 靶向免疫检查点tim3结合肽及其应用 |
| WO2021163874A1 (zh) * | 2020-02-18 | 2021-08-26 | 苏州工业园区唯可达生物科技有限公司 | 一种重组病毒载体、包含其的免疫组合物以及用途 |
| CN115698268A (zh) * | 2020-05-04 | 2023-02-03 | 萨利欧基因治疗公司 | 基于转座的疗法 |
| CN112063588A (zh) * | 2020-08-13 | 2020-12-11 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| JP2023541669A (ja) * | 2020-09-17 | 2023-10-03 | オター プロシーナ リミテッド | アルツハイマー病の処置のためのβ－アミロイドワクチン |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
| CN114907485B (zh) * | 2021-02-08 | 2024-04-26 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| CN115029317B (zh) * | 2021-02-23 | 2025-10-28 | 赛浦生物科技(长春)有限公司 | 用于过敏性鼻炎的鼻喷雾剂及制备方法 |
| US20240343767A1 (en) * | 2021-08-13 | 2024-10-17 | Shanghai Sinobay Biotechnology Co., Ltd. | Hypoxia-Triggered Artificial Transcription Factor, a Hypoxia-Triggered Transcription Control System and Use Thereof |
| US20230103980A1 (en) * | 2021-10-04 | 2023-04-06 | California Institute Of Technology | Thermal state switches in macrophages |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| US20250195658A1 (en) * | 2022-01-12 | 2025-06-19 | St. Jude Children's Research Hospital, Inc. | Bispecific chimeric antigen receptors targeting grp78 and cd123 or grp78 and b7h3 |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| US20250243279A1 (en) | 2023-10-17 | 2025-07-31 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
| WO2025129120A2 (en) * | 2023-12-15 | 2025-06-19 | Port Therapeutics, Inc. | Use of thermal bioswitches for treating autoimmune diseases |
| CN117986386B (zh) * | 2024-02-06 | 2024-11-29 | 康立泰生物医药(青岛)有限公司 | 重组人白细胞介素-35及其制备方法和应用 |
| WO2025176860A1 (en) | 2024-02-23 | 2025-08-28 | Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts | Dual chimeric antigen receptor construct targeting cea and epcam |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (cg-RX-API-DMAC7.html) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| DE68919715T2 (de) | 1988-12-28 | 1995-04-06 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| EP0557459B1 (en) | 1990-11-13 | 1997-10-22 | Immunex Corporation | Bifunctional selectable fusion genes |
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| CA2163427A1 (en) | 1993-05-21 | 1994-12-08 | Stephen D. Lupton | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
| US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
| US6653105B2 (en) | 1998-02-11 | 2003-11-25 | Vitagen, Inc. | Clonal cells and cell lines derived from C3A cells and methods of making and using them |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| WO2001010912A1 (en) * | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| US7253151B2 (en) | 2000-03-15 | 2007-08-07 | Genexine Co., Ltd. | Genes of IL-12P40 subunit mutated for improving the activity of IL-12 and use thereof for DNA vaccine adjuvant |
| US20030049787A1 (en) | 2000-03-24 | 2003-03-13 | Shyam Ramakrishnan | Regulation of human mas oncogene-related g protein-coupled receptor |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| EP1418184A1 (en) | 2002-11-08 | 2004-05-12 | Cell Center Cologne GmbH | Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof |
| GB0228465D0 (en) | 2002-12-06 | 2003-01-08 | Univ Belfast | A method of treating disease |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| ATE459648T1 (de) | 2005-05-11 | 2010-03-15 | Philogen Spa | Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12 |
| BRPI0620648B1 (pt) * | 2005-12-30 | 2022-12-20 | Merck Patent Gesellschaft Mit Beschrãnkter Haftung | Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma |
| WO2007084364A2 (en) | 2006-01-13 | 2007-07-26 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Improved il-12 for expression in mammalian cells |
| US8188220B2 (en) | 2006-12-06 | 2012-05-29 | Sanford-Burnham Medical Research Institute | Methods and compositions related to targeting wounds, regenerating tissue, and tumors |
| US8536113B2 (en) * | 2006-12-21 | 2013-09-17 | Janssen Biotech, Inc. | EGFR binding peptides and uses thereof |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| ES2654303T3 (es) | 2007-05-04 | 2018-02-13 | University Health Network | Inmunoterapia de IL-12 contra el cáncer |
| US8747290B2 (en) | 2007-12-07 | 2014-06-10 | Miltenyi Biotec Gmbh | Centrifuge for separating a sample into at least two components |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| US8715964B2 (en) | 2008-05-11 | 2014-05-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Expression of IL-12 family heterodimers |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| US8556882B2 (en) | 2009-04-30 | 2013-10-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
| WO2011112935A2 (en) | 2010-03-12 | 2011-09-15 | The Regents Of The University Of California | Antibody fusion proteins with disrupted heparin-binding activity |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| MX359513B (es) | 2011-03-23 | 2018-10-01 | Hutchinson Fred Cancer Res | Metodo y composiciones para inmunoterapia celular. |
| EP2694553B1 (en) | 2011-04-01 | 2017-10-11 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| US9580485B2 (en) | 2011-07-27 | 2017-02-28 | Philogen S.P.A. | IL-12 immunoconjugate |
| EP3326467B1 (en) | 2011-09-16 | 2020-03-11 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| CN107880101B (zh) | 2011-11-11 | 2021-12-21 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| RU2018130123A (ru) | 2012-05-03 | 2018-11-07 | Фред Хатчинсон Кансэр Рисёч Сентер | Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии |
| IL237315B (en) | 2012-08-20 | 2022-07-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| CN104781789B (zh) | 2012-12-20 | 2018-06-05 | 三菱电机株式会社 | 车载装置 |
| EP3811954A1 (en) | 2013-02-26 | 2021-04-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| WO2014139468A1 (en) * | 2013-03-15 | 2014-09-18 | Admark Healthcare, Llc | Fusion protein molecules and method of use |
| AU2014262469B2 (en) * | 2013-05-10 | 2019-11-14 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| WO2018023093A1 (en) | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
-
2017
- 2017-07-28 WO PCT/US2017/044549 patent/WO2018023093A1/en not_active Ceased
- 2017-07-28 CA CA3031955A patent/CA3031955A1/en active Pending
- 2017-07-28 ES ES17752521T patent/ES2951552T3/es active Active
- 2017-07-28 JP JP2019504812A patent/JP7295795B2/ja active Active
- 2017-07-28 AU AU2017301880A patent/AU2017301880C1/en not_active Ceased
- 2017-07-28 CN CN201780058404.8A patent/CN110087672A/zh active Pending
- 2017-07-28 MA MA045779A patent/MA45779A/fr unknown
- 2017-07-28 US US16/320,075 patent/US12304935B2/en active Active
- 2017-07-28 MX MX2019001185A patent/MX2019001185A/es unknown
- 2017-07-28 EP EP17752521.9A patent/EP3490585B1/en active Active
-
2023
- 2023-02-20 JP JP2023024001A patent/JP2023062104A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531704A5 (cg-RX-API-DMAC7.html) | ||
| CN111787951B (zh) | 影响IgM血清半衰期的IgM Fc和J链突变 | |
| CN110536900B (zh) | 调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区 | |
| CN115057936B (zh) | 异源二聚体多特异性抗体形式 | |
| ES2732907T3 (es) | Procedimiento de expresión | |
| JP5738294B2 (ja) | 抗ｖｅｇｆモノクローナル抗体およびその抗体を含む薬学的組成物 | |
| JP2024073531A5 (cg-RX-API-DMAC7.html) | ||
| JP2012515556A5 (cg-RX-API-DMAC7.html) | ||
| CN111423512B (zh) | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 | |
| FI3461261T3 (fi) | Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2019528683A (ja) | 多量体ｇｉｔｒ結合分子及びその使用 | |
| CN105194661A (zh) | 时空可调性抑制病理性靶细胞的系统 | |
| JP2020505919A5 (cg-RX-API-DMAC7.html) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| WO2022116480A1 (zh) | 含有肿瘤相关抗原taa抗体的三功能融合蛋白及其应用 | |
| CN113150156B (zh) | 抗tigit抗体及其用途 | |
| JP2023159379A (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| JP2024507693A (ja) | 二重特異性抗体 | |
| CN113490690A (zh) | 异源二聚体融合蛋白 | |
| CN116284405B (zh) | 靶向cd150蛋白的纳米抗体及其应用 | |
| JPWO2022133169A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2020071554A5 (cg-RX-API-DMAC7.html) | ||
| CN111848806B (zh) | Egfr-cd3双功能抗体及其应用 | |
| KR20220016152A (ko) | 항-gal9 결합분자 활성화 |